Seres Therapeutics Inc. (MCRB) announced Thursday morning that it plans to initiate a Phase 2 clinical study of SER-109 in patients with multiply recurrent Clostridium difficile infection.
from RTT - Before the Bell http://ift.tt/2mzoAXR
via IFTTT
No comments:
Post a Comment